[Experimental approaches to treatment of prostatic adenoma with the luliberin analog surfagon]

Therapeutic efficacy of surfagon, an analog of LH-RH which was injected subcutaneously at a daily dose of 100 micrograms/kg for 30 days, was investigated in ACI male rats with induced prostatic adenoma. This drug was shown to be effective proceeding from a morphological study and measurement of the prostate. Measurement of blood testosterone levels by radioimmunoassay showed a decrease in this level in rats, treated with surfagon, i. e. a therapeutic effect of the drug in prostatic adenoma was accompanied by a decrease in the level of androgens.